Literature DB >> 2073120

Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus.

S L Koletar1, J A Russell, R J Fass, J F Plouffe.   

Abstract

Thirty-nine adult patients with human immunodeficiency virus infection and oral candidiasis were randomly assigned to receive either one fluconazole capsule (100 mg) or five clotrimazole troches (10 mg each) daily for 14 days. Among 36 evaluable patients, clinical resolution rates were 100 and 65%, respectively (P = 0.018). Mycological eradication rates were 75 and 20%, respectively (P = 0.004). Fluconazole-treated patients were more likely to remain disease free during follow-up than those treated with clotrimazole (P = 0.014 at 2 weeks). Prolonged clinical responses correlated with mycological eradication at the end of therapy (P = 0.043).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073120      PMCID: PMC172036          DOI: 10.1128/AAC.34.11.2267

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  New triazole antifungal agents (fluconazole and itraconazole) in the treatment of HIV-related gastrointestinal candidiasis.

Authors:  D Nathwani; S T Green; W McGuire; D J Goldberg; D H Kennedy
Journal:  Scand J Infect Dis       Date:  1989

2.  Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study.

Authors:  J P Chave; A Cajot; J Bille; M P Glauser
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

3.  Use of potato flakes agar in clinical mycology.

Authors:  M G Rinaldi
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

4.  Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS.

Authors:  S De Wit; D Weerts; H Goossens; N Clumeck
Journal:  Lancet       Date:  1989-04-08       Impact factor: 79.321

Review 5.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  5 in total
  15 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharngeal candidiasis.

Authors:  Harish M Nairy; Narayana R Charyulu; Veena A Shetty; Prabhu Prabhakara
Journal:  Trials       Date:  2011-04-19       Impact factor: 2.279

Review 4.  Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.

Authors:  Elizabeth D Pienaar; Taryn Young; Haly Holmes
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 5.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

6.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

7.  Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group.

Authors:  T Hernández-Sampelayo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

8.  Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?

Authors:  J R Graybill; L K Najvar; J D Holmberg; A Correa; M F Luther
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

Review 9.  Treatment of oral Candida mucositis infections.

Authors:  G E Garber
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

10.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.